Dexcom (DXCM)
NASDAQHealth CareMedical DevicesSnapshot 2026-07-07
$73.57+1.64%
Close 2026-07-07 · 1-day change
Reading DXCM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DXCM free→NASDAQHealth CareMedical DevicesSnapshot 2026-07-07
Reading DXCM? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track DXCM free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a durable compounder with a focus on revenue growth and margin improvement. The current thesis state is stable, supported by recent earnings beats and a share buyback announcement.
The market appears to have a neutral view on DXCM, with valuations seen as cheap compared to peers. There is a slight expectations gap, suggesting that the market is not overly optimistic about future performance.
Management is focused on increasing revenue guidance, which indicates a commitment to growth. However, operating and gross profit margins are currently below long-term targets, reflecting mixed results in these areas.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT, as their earnings results could influence DXCM's trajectory. Additionally, any changes in guidance from DXCM could significantly impact market sentiment.
Overall, DXCM is positioned well for the next few years, but it faces risks from sector performance and its own guidance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat and the successful product launch support a positive outlook for DXCM. These developments indicate that the company's growth potential remains intact, enhancing its market position.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The next earnings report will show how the company is doing. This can affect market feelings.
Confirms one read:Q2 earnings beat consensus estimates by more than 10%.
Confirms the other:Q2 earnings miss consensus estimates by more than 5%.
Why it matters: A slowdown in revenue growth could signal weakening demand for Dexcom's products.
Confirms:Q2 revenue growth was less than 11% compared to last year.
Disproves:Q2 revenue growth reported at or above 11% year-over-year.
Why it matters: Progress in the share repurchase program could boost shareholder value and confidence.
Confirms:Dexcom announces completion of at least $500 million in share repurchases by Q3.
Disproves:No big share buybacks reported by Q3.
Why it matters: Rick Osterloh's skills could help Dexcom create better products.
Confirms:New products or innovations match Osterloh's skills.
Disproves:No new products or delays in product launches.
Why it matters: Operating margin shows if the company controls costs well.
Confirms one read:Q2 non-GAAP operating margin is more than 23.5%.
Confirms the other:Q2 non-GAAP operating margin is less than 23%.
Why it matters: Updates on the buyback may show that management trusts the stock's value.
Confirms:More share repurchases were announced, adding to the first $1 billion.
Disproves:No updates or a pause in the share repurchase program.
Why it matters: If revenue guidance goes up, it shows strong demand and good operations.
Confirms:Management raises revenue guidance for 2026 to more than $5.25 billion.
Disproves:Management keeps or lowers revenue guidance to less than $5.16 billion.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Better margins mean lower costs and better efficiency.
Confirms:Operating margin is expected to be over 23.5% in the next quarters.
Disproves:Operating margin is expected to be under 23% in the next quarters.